Background:
Unprecedented person-to-person transmission of MPOX (monkeypox virus) occurred in multiple countries in 2022, raising demand for diagnostic testing and generating uncertainty regarding optimal specimen types. A qualitative real-time PCR assay for the detection of MPOX DNA was validated and implemented in our clinical virology laboratory in August 2022, serving a high-risk population in both outpatient and inpatient settings.
Methods:
The assay targeting the J2L/J2R gene (LightMix Modular Monkeypox Virus, TIB Molbiol), using MagnaPure96 for nucleic acid extraction and LightCycler 480 for amplification (Roche), was validated for swabs (skin lesions, rectal, genital, throat/oral) using reference specimens provided from a public health laboratory; all other specimen types were accepted but non-validated. All clinical specimens received for MPOX testing from Aug to mid-Dec 2022 were retrospectively analyzed for cycle threshold (Ct) values correlating with approximate MPOX viral load, percent positivity, and turnaround time.
Results:
A total of 229 specimens were received from 144 unique patients (90.3% male, age range 4 to 83 years). Among patients testing positive for MPOX by any one specimen at first presentation (n=33), the mean Ct value and percent positivity varied by specimen type: Ct 22.3 for genital swabs (7/7, 100%), 22.4 for skin lesion swabs (16/16, 100%), 25.8 for rectal swabs (16/17, 94.1%), 30.3 for throat/oral swabs (12/13, 92.3%), 30.4 for urine (4/4, 100%), 35.0 for whole blood EDTA (6/7, 85.7%), and 36.3 for nasal/nasopharyngeal swabs (1/1, 100%). 29.2% of patients (42/144) had more than one specimen type submitted at the time of initial presentation; of those with confirmed MPOX infection (n=17), only 3 patients (17.6%) had one of their specimens test negative for MPOX DNA (1 blood, 1 throat, and 1 rectal swab). The average turnaround time from specimen receipt to result was < 24 hours (20h:12m). The overall positivity rate and testing volumes decreased from 34.7% (51/147 specimens) in Aug-Sep 2022 to 19.0% (8/42 specimens) in Nov-Dec 2022.
Conclusions:
Swabs of skin lesions, particularly genital lesions, demonstrated the highest approximate MPOX viral load compared to other specimen types. Submitting multiple specimen types from patients did not improve diagnostic yield when skin lesions were otherwise present. Performing MPOX testing locally in a clinical laboratory enabled prompt turnaround times for timely diagnosis, clinical management and public health intervention.